Europe Gastric Cancer Diagnostic Procedure Market

The Europe gastric cancer diagnostic procedure market was valued at US$ 464.72 million in 2022 and is projected to reach US$ 674.76 million by 2028. It is estimated to grow at a CAGR of 6.4% from 2022 to 2028.

Rise in Prevalence of Gastrointestinal Diseases Fuels Europe Gastric Cancer Diagnostic Procedure Market

Heartburn, inflammatory bowel diseases (IBD), inflammatory bowel syndrome (IBS), constipation, and diarrhea are among the common digestive problems. Gastrointestinal (GI) diseases account for substantial healthcare utilization and spending. The stomach is lined with a mucous membrane composed of cells and glands. The cells are prone to inflammation, leading to peptic ulcers, which may potentially develop into gastric cancer. Problems caused by stomach acid backflowing into the esophagus, known as gastroesophageal reflux disease (GERD), also increase the risk of developing gastric cancer. Despite declining incidence and mortality during the last decades, stomach cancer is perceived as one of the main health challenges. The prevalence of irritable bowel syndrome (IBS) has increased across the region in the last few decades. In contrast to a decline in the overall incidence of gastric cancer, it has surged among young adults in the last few decades. Thus, the increasing prevalence of gastrointestinal (GI) disease results in a high risk of developing gastric cancer, which drives the growth of the gastric cancer diagnostic procedures market.

Europe Gastric Cancer Diagnostic Procedure Market Overview

The Europe gastric cancer diagnostic procedure market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant share of the global gastric cancer diagnostic procedure market. The market in Europe is expected to witness significant growth during the forecast period due to factors such as the high incidence of stomach cancer and Helicobacter pylori infection, growth in the geriatric population, and efforts made by various institutes to spread awareness of gastric cancer. Germany is one of the fastest-growing markets for gastric cancer diagnostic procedures in Europe. According to The Robert Koch Institute, H. pylori and Epstein-Barr virus infections are reported to be the major cause of stomach cancer. Germany reports a high incidence of H. pylori infection. According to a study published in Clinical Microbiology and Infection Journal (ELSEVIER) in 2020, H. pylori infected ~25% of the total population in Germany and caused gastritis that becomes more complicated with gastric adenocarcinoma.

Europe Gastric Cancer Diagnostic Procedure Market Revenue and Forecast to 2028 (US$ Million)

Europe Gastric Cancer Diagnostic Procedure Strategic Insights

Strategic insights for the Europe Gastric Cancer Diagnostic Procedure provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Gastric Cancer Diagnostic Procedure Report Scope

Europe Gastric Cancer Diagnostic Procedure Regional Insights

The geographic scope of the Europe Gastric Cancer Diagnostic Procedure refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Europe Gastric Cancer Diagnostic Procedure Market Segmentation

The Europe gastric cancer diagnostic procedure market is segmented into healthcare provider, symptom type, body fluid, procedure, offering, disease indication, and country.

Based on healthcare provider, the Europe gastric cancer diagnostic procedure market is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, and others. The hospitals segment held the largest market share in 2022. In terms of body fluid, the Europe gastric cancer diagnostic procedure market is segmented into blood, urine, saliva, stomach wash/gastric juice, tissue, and others. The blood segment held the largest market share in 2022. The Europe gastric cancer diagnostic procedure market, by offering, is segmented into instruments, reagents & consumables, and services. The reagents & consumables segment held the largest market share in 2022.

Based on diagnostic procedure, the Europe gastric cancer diagnostic procedure market is categorized into endoscopic procedures, biopsy and tissue tests, lab tests, in-vitro diagnostic tests, imaging tests, molecular diagnostics, multiplexing molecular diagnostics, immunoassays, and others. The imaging segment held the largest share of the market in 2022. The Europe gastric cancer diagnostic procedure market, based on disease condition, is bifurcated into early gastric cancer and advanced type gastric cancer. The advanced type gastric cancer segment held a larger market share in 2022.

Based on country, the Europe gastric cancer diagnostic procedure market has been categorized into the UK, Germany, France, Italy, Spain, and Rest of Europe. Germany dominated the market in this region in 2022.

Agilent Technologies Inc, Atlas-Link Biotech Co Ltd, BioMerieux SA, Bio-Rad Laboratories Inc, F. Hoffmann-La Roche Ltd, Illumina Inc, Myraid Genetics Inc, Thermo Fisher Scientific Inc, and Vela Diagnostics Holding Pte Ltd. are the leading companies operating in the Europe gastric cancer diagnostic procedure market.